Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VENKATESH K NADAR

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1154383826
CMS profile
187941
Location
CAMP HILL, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$21,345.77

237 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $16,789.40 49
Food and Beverage $4,556.37 188

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VENKATESH K NADAR

NPI 1154383826 · CMS profile ID 187941

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

CAMP HILL, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1154383826?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VENKATESH K NADAR, NPI 1154383826, CMS profile ID 187941. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1154383826?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). VENKATESH K NADAR, NPI 1154383826, CMS profile ID 187941. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1154383826?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
VENKATESH K NADAR, NPI 1154383826, CMS profile ID 187941, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 237 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1154383826?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

237 matching records · $21,345.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 237 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 237.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.0309/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020185331 CMS
E.R. Squibb & Sons, L.L.C. $0.2009/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015823993 CMS
ShockWave Medical, Inc $18.2009/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058519245 CMS
Daiichi Sankyo Inc. $18.0609/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006499279 CMS
PFIZER INC. $17.6909/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050451597 CMS
PFIZER INC. $10.8209/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050506991 CMS
Daiichi Sankyo Inc. $25.4009/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006503353 CMS
Boehringer Ingelheim International GmbH $820.4109/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1017331251 CMS
AstraZeneca Pharmaceuticals LP $14.2508/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025073105 CMS
Esperion Therapeutics, Inc. $16.7808/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050743639 CMS
Kiniksa Pharmaceuticals, Ltd. $27.1308/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058930771 CMS
E.R. Squibb & Sons, L.L.C. $21.0608/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015823971 CMS
E.R. Squibb & Sons, L.L.C. $0.3208/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015823975 CMS
E.R. Squibb & Sons, L.L.C. $1.1108/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015823981 CMS
Daiichi Sankyo Inc. $13.8008/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006473697 CMS
AstraZeneca Pharmaceuticals LP $13.5008/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025039791 CMS
Novartis Pharmaceuticals Corporation $1.6108/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992728287 CMS
Novartis Pharmaceuticals Corporation $27.3108/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992728291 CMS
Merck Sharp & Dohme LLC $763.9708/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048443391 CMS
Merck Sharp & Dohme LLC $57.9908/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048443395 CMS
Merck Sharp & Dohme LLC $20.0008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048443399 CMS
Merck Sharp & Dohme LLC $75.0008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048447949 CMS
Merck Sharp & Dohme LLC $40.0008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048447953 CMS
Merck Sharp & Dohme LLC $174.8508/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048443387 CMS
Merck Sharp & Dohme LLC $96.9608/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048443641 CMS
Merck Sharp & Dohme LLC $47.0308/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048779409 CMS
Merck Sharp & Dohme LLC $138.3708/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048782993 CMS
Merck Sharp & Dohme LLC $196.7208/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048782997 CMS
Novo Nordisk Inc $11.8408/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002624373 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.3708/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996857439 CMS
Daiichi Sankyo Inc. $8.2608/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006473843 CMS
PFIZER INC. $3.1008/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050656075 CMS
AstraZeneca Pharmaceuticals LP $15.0508/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025002071 CMS
PFIZER INC. $13.9108/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050680757 CMS
ShockWave Medical, Inc $70.6108/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058531687 CMS
BIOTRONIK INC. $22.5008/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051715815 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.1508/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996857443 CMS
Daiichi Sankyo Inc. $14.7307/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006473713 CMS
Esperion Therapeutics, Inc. $16.2607/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050743637 CMS
Amgen Inc. $15.0907/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020185327 CMS
Janssen Pharmaceuticals, Inc $17.7107/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987912613 CMS
AstraZeneca Pharmaceuticals LP $14.6507/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025000085 CMS
Impulse Dynamics (USA) Inc. $17.7507/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022363767 CMS
E.R. Squibb & Sons, L.L.C. $21.6507/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015823951 CMS
PFIZER INC. $4.1607/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050680755 CMS
PFIZER INC. $0.5207/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050703053 CMS
PFIZER INC. $18.3707/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050637521 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1807/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996857445 CMS
Novartis Pharmaceuticals Corporation $28.4007/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992728283 CMS
PFIZER INC. $15.0007/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050519973 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,835.04 133
PY2020 $2,338.93 132
PY2021 $3,520.57 174
PY2022 $2,638.06 147
PY2023 $21,345.77 237
PY2024 $9,694.81 202
PY2025 $2,993.08 137

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,422,870.52 276
PY2024 Recipient $39,797.00 2
PY2024 Principal investigator $2,947,044.76 148
PY2023 Recipient $857.97 2
PY2023 Principal investigator $3,176,608.43 319
PY2022 Recipient $5,774.00 3
PY2022 Principal investigator $3,440,257.96 262
PY2021 Principal investigator $1,745,181.81 311
PY2020 Recipient $2,445.30 3
PY2020 Principal investigator $1,734,293.59 133
PY2019 Recipient $2,576.33 2
PY2019 Principal investigator $1,805,576.75 170

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

276 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $506.25 12/31/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228733364
Principal investigator 1 Cleerly, Inc. $791.70 12/30/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149079
Principal investigator 1 PFIZER INC. $3,577.77 12/30/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228745836
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 12/17/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781320
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 12/17/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781322
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 12/17/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781324
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/15/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220999011
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 12/15/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817452
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,028.00 12/15/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817456
Principal investigator 1 Cleerly, Inc. $3,390.40 12/12/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149127
Principal investigator 1 Janssen Research & Development, LLC $8,136.00 12/12/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264695
Principal investigator 1 PFIZER INC. $11,000.00 12/12/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228745199
Principal investigator 1 PFIZER INC. $4,500.00 12/11/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228743739
Principal investigator 1 PFIZER INC. $16,274.79 12/11/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228749805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,250.00 12/10/2025 Non-covered Recipient Entity
Capital Area Research, LLC
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215520025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,598.00 12/10/2025 Non-covered Recipient Entity
Capital Area Research, LLC
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215520030
Principal investigator 1 Cleerly, Inc. $11,339.90 12/02/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149108
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781302
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781304
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781306
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781308
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781310
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781312
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220781326
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220781328
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220781330
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 12/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220781332
Principal investigator 1 AstraZeneca Pharmaceuticals LP $42,689.30 11/26/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185537231
Principal investigator 1 PFIZER INC. $18,966.09 11/26/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228728467
Principal investigator 1 PFIZER INC. $6,211.35 11/25/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228714731
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228725226
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228731803
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735244
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735279
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735420
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735426
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735632
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735637
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228735718
Principal investigator 1 PFIZER INC. $426.60 11/21/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228738858
Principal investigator 1 Janssen Research & Development, LLC $13,416.00 11/19/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264856
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,331.40 11/13/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817454
Principal investigator 1 PFIZER INC. $180.80 11/12/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228723724
Principal investigator 1 PFIZER INC. $265.20 11/12/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228723920
Principal investigator 1 Cleerly, Inc. $1,043.90 11/07/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149067
Principal investigator 1 Janssen Research & Development, LLC $13,634.00 11/07/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264880
Principal investigator 1 Janssen Research & Development, LLC $35,336.00 11/06/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264669
Principal investigator 1 Janssen Research & Development, LLC $30,912.00 11/06/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264864
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,157.45 11/05/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185537237
Principal investigator 1 Cleerly, Inc. $29,307.20 11/05/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149095
Principal investigator 1 PFIZER INC. $13,749.87 11/04/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228719937
Principal investigator 1 Janssen Research & Development, LLC $480.00 11/03/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264733
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,324.64 11/03/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190303835
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781290
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781292
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781294
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781296
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781298
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781300
Principal investigator 1 PFIZER INC. $16,237.80 10/30/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228742258
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781314
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 10/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781316
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 10/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781318
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 10/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220781334
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 10/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220781336
Principal investigator 1 Janssen Research & Development, LLC $5,986.00 10/27/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175370152
Principal investigator 1 PFIZER INC. $8,754.75 10/17/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228741945
Principal investigator 1 Cleerly, Inc. $12,899.90 10/08/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149056
Principal investigator 1 Cleerly, Inc. $1,571.70 10/07/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149063
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781278
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781280
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781282
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781284
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781286
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781288
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 09/24/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781276
Principal investigator 1 PFIZER INC. $17,986.40 09/24/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228769007
Principal investigator 1 Janssen Research & Development, LLC $16,727.00 09/19/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264842
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,489.80 09/18/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817450
Principal investigator 1 Janssen Research & Development, LLC $66,600.00 09/17/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264722
Principal investigator 1 PFIZER INC. $6,977.62 09/09/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228757459
Principal investigator 1 Cleerly, Inc. $1,680.90 09/05/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149011
Principal investigator 1 Cleerly, Inc. $25,543.70 09/05/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149041
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781234
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781246
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781248
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781250
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781252
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781254
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781270
Principal investigator 1 Janssen Research & Development, LLC $23,740.00 09/01/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264686
Principal investigator 1 PFIZER INC. $22,449.17 08/26/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228768291
Principal investigator 1 Janssen Research & Development, LLC $16,773.00 08/25/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264760
Principal investigator 1 Janssen Research & Development, LLC $3,977.00 08/14/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264599
Principal investigator 1 Janssen Research & Development, LLC $3,589.00 08/14/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264677
Principal investigator 1 PFIZER INC. $3,412.80 08/11/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228714811
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,800.20 08/06/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817448
Principal investigator 1 PFIZER INC. $36,669.46 08/05/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228768175
Principal investigator 1 Cleerly, Inc. $18,870.80 08/04/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241149029
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781236
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781238
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781240
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781242
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781244
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781268
Principal investigator 1 Cleerly, Inc. $1,695.20 07/31/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148988
Principal investigator 1 Cleerly, Inc. $2,507.70 07/31/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148996
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,155.80 07/30/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190302273
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 07/28/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781272
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 07/28/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781274
Principal investigator 1 Janssen Research & Development, LLC $1,911.00 07/28/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264804
Principal investigator 1 Janssen Research & Development, LLC $36,189.00 07/28/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264849
Principal investigator 1 Janssen Research & Development, LLC $11,358.00 07/23/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264728
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,575.15 07/16/2025 Non-covered Recipient Entity
Capital Area Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520004
Principal investigator 1 PFIZER INC. $32,870.62 07/15/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228787175
Principal investigator 1 PFIZER INC. $916.38 07/10/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228784118
Principal investigator 1 Cleerly, Inc. $18,107.70 07/08/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148950
Principal investigator 1 PFIZER INC. $331.89 07/07/2025 Non-covered Recipient Entity
Capital Area Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228714729
Principal investigator 1 PFIZER INC. $283.13 07/07/2025 Non-covered Recipient Entity
Capital Area Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228714733
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781256
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781258
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781260
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781262
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781264
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781266
Principal investigator 1 Cleerly, Inc. $2,705.30 06/27/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148968
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,480.80 06/26/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817446
Principal investigator 1 PFIZER INC. $41,169.88 06/26/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228776661
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 06/24/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781230
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781232
Principal investigator 1 Cleerly, Inc. $1,736.80 06/23/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148910
Principal investigator 1 Janssen Research & Development, LLC $7,277.00 06/23/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264832
Principal investigator 1 Amgen Inc. $103,541.97 06/22/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246639907
Principal investigator 1 Janssen Research & Development, LLC $13,895.00 06/20/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264637
Principal investigator 1 Janssen Research & Development, LLC $3,158.00 06/20/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264766
Principal investigator 1 Janssen Research & Development, LLC $2,680.00 06/20/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264794
Principal investigator 1 Cleerly, Inc. $21,171.80 06/02/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148937
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781208
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781210
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781212
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781214
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781216
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781218
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781220
Principal investigator 1 PFIZER INC. $9,880.17 05/31/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228772897
Principal investigator 1 Janssen Research & Development, LLC $4,705.00 05/28/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264752
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 05/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781226
Principal investigator 1 Boehringer Ingelheim International GmbH $5.22 05/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781228
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,100.00 05/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817444
Principal investigator 1 Janssen Research & Development, LLC $11,351.00 05/23/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes No dispute reported 06/30/2026 1175370162
Principal investigator 1 Janssen Research & Development, LLC $14,141.00 05/21/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264612
Principal investigator 1 Janssen Research & Development, LLC $12,568.00 05/20/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264630
Principal investigator 1 Janssen Research & Development, LLC $1,675.00 05/20/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264789
Principal investigator 1 PFIZER INC. $1,832.76 05/20/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228782578
Principal investigator 1 PFIZER INC. $50,607.40 05/14/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228764249
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,706.50 05/09/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817442
Principal investigator 1 Cleerly, Inc. $27,952.60 05/06/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148924
Principal investigator 1 Janssen Research & Development, LLC $3,600.00 05/06/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264782
Principal investigator 1 PFIZER INC. $24,637.30 05/06/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228771836
Principal investigator 1 PFIZER INC. $916.38 05/06/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228773295
Principal investigator 1 PFIZER INC. $14,761.30 05/03/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228763608
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781196
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781198
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781200
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781202
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781204
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781206
Principal investigator 1 PFIZER INC. $96,000.00 04/30/2025 Non-covered Recipient Entity
Capital Area Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228780564
Principal investigator 1 Cleerly, Inc. $4,664.40 04/25/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148891
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 04/23/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781222
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 04/23/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781224
Principal investigator 1 Janssen Research & Development, LLC $15,013.00 04/23/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $717.76 04/18/2025 Non-covered Recipient Entity
Capital Area Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519938
Principal investigator 1 PFIZER INC. $31,017.28 04/18/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228795756
Principal investigator 1 Janssen Research & Development, LLC $18,071.00 04/17/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264647
Principal investigator 1 Janssen Research & Development, LLC $8,460.00 04/17/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264714
Principal investigator 1 PFIZER INC. $8,247.42 04/16/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228796518
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,019.80 04/11/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817440
Principal investigator 1 PFIZER INC. $3,665.52 04/10/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228793809
Principal investigator 1 Cleerly, Inc. $17,888.00 04/07/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148870
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781184
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781186
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781188
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781190
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781192
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781194
Principal investigator 1 Novo Nordisk AS $9,850.00 03/31/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
NN9535-4533 No dispute reported 06/30/2026 1213727809
Principal investigator 1 Novo Nordisk AS $4,540.00 03/31/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
NN9535-4533 No dispute reported 06/30/2026 1213824692
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 03/25/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781174
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 03/25/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781176
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 03/25/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781178
Principal investigator 1 Boehringer Ingelheim International GmbH $5.52 03/25/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781180
Principal investigator 1 Janssen Research & Development, LLC $20,062.00 03/25/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264706
Principal investigator 1 Janssen Research & Development, LLC $11,320.00 03/25/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264743
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,830.40 03/24/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817438
Principal investigator 1 PFIZER INC. $43,020.65 03/22/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228779425
Principal investigator 1 Janssen Research & Development, LLC $16,365.00 03/21/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264899
Principal investigator 1 Eli Lilly and Company $58.67 03/18/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187880627
Principal investigator 1 Cleerly, Inc. $3,554.20 03/11/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148850
Principal investigator 1 Cleerly, Inc. $13,410.80 03/10/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148858
Principal investigator 1 PFIZER INC. $2,749.14 03/04/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228720401
Principal investigator 1 PFIZER INC. $1,578.76 03/04/2025 Non-covered Recipient Entity
Capital Area Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228781281
Principal investigator 1 PFIZER INC. $1,854.02 03/04/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228782138
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781142
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781144
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781146
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781148
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781150
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781152
Principal investigator 1 PFIZER INC. $2,454.39 02/28/2025 Non-covered Recipient Entity
Capital Area Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228770744
Principal investigator 1 Janssen Research & Development, LLC $13,912.00 02/27/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264819
Principal investigator 1 Janssen Research & Development, LLC $15,416.00 02/27/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264825
Principal investigator 1 Janssen Research & Development, LLC $14,457.00 02/27/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264871
Principal investigator 1 Janssen Research & Development, LLC $1,250.00 02/27/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264908
Principal investigator 1 Amgen Inc. $286,040.84 02/25/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight No dispute reported 06/30/2026 1246639905
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 02/25/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781170
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 02/25/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781172
Principal investigator 1 Janssen Research & Development, LLC $5,063.00 02/19/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264606
Principal investigator 1 Janssen Research & Development, LLC $12,787.00 02/19/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264774
Principal investigator 1 Novo Nordisk AS $6,094.06 02/19/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
NN9535-4533 No dispute reported 06/30/2026 1213759963
Principal investigator 1 Janssen Research & Development, LLC $4,022.00 02/18/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264653
Principal investigator 1 PFIZER INC. $15,171.58 02/14/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 2A RANDOMIZED DOUBLEBLIND SPONSOROPEN PLACEBOCONTROLLED PARALLEL GROUP DOSERANGING STUDY OF PF07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY No dispute reported 06/30/2026 1228750302
Principal investigator 1 Novo Nordisk AS $750.00 02/12/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
NN9535-4533 No dispute reported 06/30/2026 1213805188
Principal investigator 1 Eli Lilly and Company $11,500.00 02/10/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A STUDY OF LY3819469 IN PARTICIPANTS WITH ELEVATED LIPOPROTEIN(A) [LP(A)] No dispute reported 06/30/2026 1187876525
Principal investigator 1 Cleerly, Inc. $8,450.00 02/07/2025 Non-covered Recipient Entity
Capital Area Research, LLC
TRANSFORM No dispute reported 06/30/2026 1241148845
Principal investigator 1 PFIZER INC. $4,702.43 02/05/2025 Non-covered Recipient Entity
Capital Area Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228723482
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781130
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781132
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781134
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781136
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781138
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781140
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,750.52 01/29/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185537233
Principal investigator 1 Eli Lilly and Company $4,522.89 01/29/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187880621
Principal investigator 1 Amgen Inc. $24,487.77 01/27/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246639901
Principal investigator 1 Boehringer Ingelheim International GmbH $46.64 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781154
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781156
Principal investigator 1 Boehringer Ingelheim International GmbH $474.50 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781158
Principal investigator 1 Boehringer Ingelheim International GmbH $663.30 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781160
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781162
Principal investigator 1 Boehringer Ingelheim International GmbH $1.45 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781164
Principal investigator 1 Boehringer Ingelheim International GmbH $15.66 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781166
Principal investigator 1 Boehringer Ingelheim International GmbH $22.08 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781168
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,207.00 01/27/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817436
Principal investigator 1 Eli Lilly and Company $263.75 01/27/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187877257
Principal investigator 1 Eli Lilly and Company $4,348.32 01/27/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187880625
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 01/23/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817434
Principal investigator 1 Janssen Research & Development, LLC $30,099.00 01/22/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175264888
Principal investigator 1 Eli Lilly and Company $72,017.00 01/21/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187877959
Principal investigator 1 Janssen Research & Development, LLC $5,969.00 01/21/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264623
Principal investigator 1 Janssen Research & Development, LLC $19,475.00 01/21/2025 Non-covered Recipient Entity
Cptal Area Rsrch Llc
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175264661
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,378.29 01/21/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190302271
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,887.80 01/17/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817430
Principal investigator 1 PFIZER INC. $1,115.10 01/14/2025 Non-covered Recipient Entity
Capital Area Research LLC
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1228799773
Principal investigator 1 Novartis Pharmaceuticals Corporation $435,007.00 01/13/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190311151
Principal investigator 1 PFIZER INC. $818.13 01/10/2025 Non-covered Recipient Entity
Capital Area Research LLC
A LOWINTERVENTIONAL PROSPECTIVE LONGITUDINAL COHORT STUDY TO COLLECT DIGITAL FUNCTIONAL ASSESSMENTS AND EVALUATE SYMPTOMS IN STUDY PARTICIPANTS WITH CHRONIC HEART FAILURE No dispute reported 06/30/2026 1228798324
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,984.33 01/08/2025 Non-covered Recipient Entity
Capital Area Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519844
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,459.05 01/08/2025 Non-covered Recipient Entity
Capital Area Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519848
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,068.58 01/08/2025 Non-covered Recipient Entity
Capital Area Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519852
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,627.32 01/08/2025 Non-covered Recipient Entity
Capital Area Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,624.92 01/08/2025 Non-covered Recipient Entity
Capital Area Research, LLC
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215519861
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 01/07/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220817432
Principal investigator 1 Eli Lilly and Company $127,676.00 01/07/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187876477
Principal investigator 1 Eli Lilly and Company $203,338.00 01/07/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187876527
Principal investigator 1 Eli Lilly and Company $139,483.00 01/07/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187878343
Principal investigator 1 Eli Lilly and Company $71,130.00 01/07/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187880623
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,343.65 01/03/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185537229
Principal investigator 1 AstraZeneca Pharmaceuticals LP $16,200.00 01/03/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185537235
Principal investigator 1 Amgen Inc. $85,910.60 01/02/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke No dispute reported 06/30/2026 1246639903
Principal investigator 1 Eli Lilly and Company $4,362.90 01/02/2025 Non-covered Recipient Entity
CAPITAL AREA RESEARCH LLC
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187880629
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781120
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781122
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781124
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781126
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781128
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Capital Area Research LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220781182